| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972882 | OTSUKA | Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists |
Dec, 2018
(5 years ago) | |
| US5753677 | OTSUKA | Benzoheterocyclic compounds |
May, 2020
(3 years ago) | |
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
Jynarque is owned by Otsuka.
Jynarque contains Tolvaptan.
Jynarque has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Jynarque are:
- US5972882
- US5753677
Jynarque was authorised for market use on 23 April, 2018.
Jynarque is available in tablet;oral dosage forms.
Jynarque can be used as treatment of autosomal dominant polycystic kidney disease.
The generics of Jynarque are possible to be released after 07 April, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-178) | Apr 23, 2025 |
| New Indication(I-779) | Apr 23, 2021 |
Drugs and Companies using TOLVAPTAN ingredient
Market Authorisation Date: 23 April, 2018
Treatment: Treatment of autosomal dominant polycystic kidney disease
Dosage: TABLET;ORAL
How can I launch a generic of JYNARQUE before it's drug patent expiration?
More Information on Dosage
JYNARQUE family patents
